Tilray Brands Inc vs DENTSPLY SIRONA Inc — how do they compare? Tilray Brands Inc trades at $4.25 (market cap $524.07M), while DENTSPLY SIRONA Inc trades at $13.56 (market cap $2.70B). The key difference: DENTSPLY SIRONA Inc is far larger — about 5.2× Tilray Brands Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| TLRY | XRAY | |
|---|---|---|
Market Cap | $524.07M | $2.70B |
Sector | Health | Health |
52-Week High | $21.00 | $16.85 |
52-Week Low | $4.23 | $9.64 |
Enterprise Value | $621.22M | $4.84B |
Dividend Yield | — | 5.04% |
Signals from Pluang's Aura AI — not financial advice
TLRY trades at $4.23, down 1.63% on the day, with a bearish technical signal and negative earnings trends. The company reported a net loss of $2.19 billion in 2025 despite revenue growth to $821.31 million, reflecting deep profitability challenges. Analysts show cautious sentiment with 65% hold ratings, while recent news highlights expansion in medical cannabis and beverage segments amid ongoing regulatory uncertainty.
The outlook remains challenged by persistent losses and high debt-to-asset ratio of 12.25, though low P/S and P/B ratios suggest undervaluation. Key risks include profitability execution and federal cannabis policy shifts, while potential catalysts lie in international expansion and cost management improvements.
Dentsply Sirona (XRAY) trades at $13.65, down 2.91% on the day, with a mixed technical picture showing a bullish moving average signal but overbought RSI levels. Fundamentally, the company reported a net loss of $598 million for 2025, with negative profit margins and an elevated EV/EBITDA of 91.48, though revenue remains stable near $3.7 billion. Recent news includes the appointment of a new CFO and expanded U.S. distribution partnerships, while the upcoming Q2 2026 earnings call on August 6 is a key near-term catalyst.
The outlook remains challenging due to persistent losses and margin pressure, offset by strategic growth initiatives. Investment opportunities lie in the company's market leadership and digital dentistry expansion, but risks include high debt levels, competitive pressures, and the need for a successful turnaround. Analyst consensus is Hold with a price target of $13.33, indicating limited near-term upside from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →